Stelara Biosimilar Nods Arrive In US And EU For Fresenius And Formycon

Simultaneous Approvals For Partners Will Pave Way For Ustekinumab Launches In Key Markets

 
• By Dave Wallace

Fresenius and Formycon have celebrated simultaneous US and EU approvals for the firms’ partnered Otulfi ustekinumab rival to Stelara. And with competing biosimilars already available on the European market, all eyes will soon be on US launches at the start of 2025, with Fresenius providing a significant update on launch timing.

Darts with EU and US flags hitting bullseye
The EU and US ustekinumab applications have hit the target • Source: Shutterstock

More from Biosimilars

More from Products